Journal Article

PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

Citarella, Fabrizio, Talbot, Thomas, Filetti, Marco, Buti, Sebastiano, Stucci, Luigia S., Tucci, Marco, Ficorella, Corrado, Marconcini, Riccardo, De Tursi, Michele, Porzio, Giampiero, Cortellini, Alessio, Santini, Daniele, Mallardo, Domenico, Pinato, David J., Di Marino, Pietro, Adamo, Vincenzo, Bersanelli, Melissa, Marchetti, Paolo, Ghidini, Michele, Nigro, Olga, Queirolo, Paola, Inno, Alessandro, Spagnolo, Francesco, Zeppola, Tea, Gelibter, Alain, Giorgi, Francesca Chiara, Tanda, Enrica T., Nicolardi, Linda, Chiari, Rita, Anesi, Cecilia, Siringo, Marco, Bracarda, Sergio, Giusti, Raffaele, Mazzaschi, Giulia, Zoratto, Federica, Vitale, Maria Grazia, Pala, Laura, Macrini, Serena, Ferrari, Marco, Grossi, Francesco, Sergi, Maria Chiara, Ascierto, Paolo A., Rastelli, Francesca, Russano, Marco, Botticelli, Andrea, Gori, Stefania, Vitale, Maria Giuseppa, Russo, Alessandro

2021

Overview

Background The favourable safety profile and the increasing confidence with immune checkpoint inhibitors (ICIs) might have boosted their prescription in frail patients with short life expectancies, who usually are not treated with standard chemotherapy. Methods The present analysis aims to describe clinicians’ attitudes towards ICIs administration during late stages of life within a multicenter cohort of advanced cancer patients treated with single agent PD-1/PD-L1 checkpoint inhibitors in Italy. Results Overall, 1149 patients with advanced cancer who received single agent PD-1/PD-L1 checkpoint inhibitors were screened. The final study population consisted of 567 deceased patients. 166 patients (29.3%) had received ICIs within 30 days of death; among them there was a significantly higher proportion of patients with ECOG-PS ≥ 2 (28.3% vs 11.5%, p < 0.0001) and with a higher burden of disease (69.3% vs 59.4%, p = 0.0266). In total, 35 patients (6.2%) started ICIs within 30 days of death; among them there was a higher proportion of patients with ECOG-PS ≥ 2 (45.7% vs 14.5%, p < 0.0001) and with a higher burden of disease (82.9% vs 60.9%, p = 0.0266). Primary tumors were significantly different across subgroups (p = 0.0172), with a higher prevalence of NSCLC patients (80% vs 60.9%) among those who started ICIs within 30 days of death. Lastly, 123 patients (21.7%) started ICIs within 3 months of death. Similarly, within this subgroup there was a higher proportion of patients with ECOG-PS ≥ 2 (29.3% vs 12.8%, p < 0.0001), with a higher burden of disease (74.0% vs 59.0%, p = 0.0025) and with NSCLC (74.0% vs 58.8%, p = 0.0236). Conclusion Our results confirmed a trend toward an increasing ICIs prescription in frail patients, during the late stages of life. Caution should be exercised when evaluating an ICI treatment for patients with a poor PS and a high burden of disease.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Age / Appropriateness / Attitudes / B7-H1 Antigen / Biomedical and Life Sciences / Biomedicine / Cancer / Cancer therapies / Care and treatment / Chemotherapy / Clinical medicine / Combination strategies / Death / End-of-life / Gender / Humans / Immune Checkpoint Inhibitors / Immunotherapy / Italy / Kidney cancer / Lung cancer / Lung Neoplasms - drug therapy / Medicine/Public Health / Melanoma / Methods / Monoclonal antibodies / Non-small cell lung carcinoma / Palliative care / Palliative treatment / Patients / PD-1 protein / PD-L1 protein / Population studies / Programmed Cell Death 1 Receptor / Software / Trends / Tumors